Medicamen Biotech Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹669.5
- Today's High:
- ₹705
- Open Price:
- ₹701
- 52W Low:
- ₹602.05
- 52W High:
- ₹1169.9
- Prev. Close:
- ₹699.7
- Volume:
- 5121
Company Statistics
- Market Cap.:
- ₹9.24 billion
- Book Value:
- 155.503
- Revenue TTM:
- ₹1.50 billion
- Operating Margin TTM:
- 12.45%
- Gross Profit TTM:
- ₹712.36 million
- Profit Margin:
- 10.31%
- Return on Assets TTM:
- 4.34%
- Return on Equity TTM:
- 8.67%
Company Profile
Medicamen Biotech Limited had its IPO on under the ticker symbol MEDICAMEQ.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Medicamen Biotech Limited has a staff strength of 0 employees.
Stock update
Shares of Medicamen Biotech Limited opened at ₹701 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹669.5 - ₹705, and closed at ₹678.45.
This is a -3.04% slip from the previous day's closing price.
A total volume of 5,121 shares were traded at the close of the day’s session.
In the last one week, shares of Medicamen Biotech Limited have slipped by -5.54%.
Medicamen Biotech Limited's Key Ratios
Medicamen Biotech Limited has a market cap of ₹9.24 billion, indicating a price to book ratio of 5.6969 and a price to sales ratio of 8.5262.
In the last 12-months Medicamen Biotech Limited’s revenue was ₹1.50 billion with a gross profit of ₹712.36 million and an EBITDA of ₹251.76 million. The EBITDA ratio measures Medicamen Biotech Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Medicamen Biotech Limited’s operating margin was 12.45% while its return on assets stood at 4.34% with a return of equity of 8.67%.
In Q2, Medicamen Biotech Limited’s quarterly earnings growth was a positive 6.1% while revenue growth was a positive 26.8%.
Medicamen Biotech Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 61.0359
- PEG
Its diluted EPS in the last 12-months stands at ₹11.97 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Medicamen Biotech Limited’s profitability.
Medicamen Biotech Limited stock is trading at a EV to sales ratio of 8.6584 and a EV to EBITDA ratio of 41.5341. Its price to sales ratio in the trailing 12-months stood at 8.5262.
Medicamen Biotech Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 17.16%.
Balance sheet and cash flow metrics
- Total Assets
- ₹2.79 billion
- Total Liabilities
- ₹825.74 million
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 17.16%
Medicamen Biotech Limited ended 2024 with ₹2.79 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹2.79 billion while shareholder equity stood at ₹1.93 billion.
Medicamen Biotech Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹825.74 million in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹207.79 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹8.70 million.
Medicamen Biotech Limited’s total current assets stands at ₹1.63 billion while long-term investments were ₹0 and short-term investments were ₹0. Its net receivables were ₹652.58 million compared to accounts payable of ₹475.86 million and inventory worth ₹450.57 million.
In 2024, Medicamen Biotech Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Medicamen Biotech Limited paid ₹0.17 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹678.45
- 52-Week High
- ₹1169.9
- 52-Week Low
- ₹602.05
- Analyst Target Price
- ₹
Medicamen Biotech Limited stock is currently trading at ₹678.45 per share. It touched a 52-week high of ₹1169.9 and a 52-week low of ₹1169.9. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹752.03 and 200-day moving average was ₹735.91 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5984% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Medicamen Biotech Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Medicamen Biotech Limited researches, develops, manufactures, markets, sells, and distributes pharmaceutical formulations and APIs in India. The company offers a range of products, including tablets, such as non-beta lactam tablets; capsules comprising beta and non-beta lactam capsules; liquid and dry syrups; and ointments and creams. It also provides oral solid and liquid products. The company’s products are used in various therapeutic areas, such as gastrointestinal, pain management, anti-infectives, pediatrics, dermatology, gynecology and rheumatology, diabetology, cardiology, oncology, and the central nervous system. Medicamen Biotech Limited was incorporated in 1993 and is based in New Delhi, India.